Literature DB >> 23054499

Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients.

Chun Fan Lee1, Nan Luo, Raymond Ng, Nan Soon Wong, Yoon Sim Yap, Soo Kien Lo, Whay Kuang Chia, Alethea Yee, Lalit Krishna, Celest Wong, Cynthia Goh, Yin Bun Cheung.   

Abstract

PURPOSE: To compare the measurement precision and related properties between the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire and the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire in assessing breast cancer patients.
METHODS: An observational study of 269 Singaporean breast cancer patients. To compare discriminative ability and responsiveness, the effect sizes (in standard deviation) of the EQ-5D-5L and the FACT-B in relation to health indicators and the change in performance status or quality of life were estimated. Test-retest reliability was examined using the intraclass correlation (ICC).
RESULTS: Using performance status, evidence of disease, and treatment status as the criteria, the differences (FACT-B minus EQ-5D-5L) in the effect size for discriminative ability were negative or closed to zero, and the 90% confidence intervals totally fell within the zone that indicated the non-inferiority of the EQ-5D-5L. For responsiveness and test-retest reliability, the confidence intervals of the differences in effect size and ICC overlapped the non-inferiority margin; thus, non-inferiority in these two aspects could neither be confirmed nor rejected.
CONCLUSIONS: The EQ-5D-5L was non-inferior to the FACT-B in discriminating breast cancer patients with different health conditions cross-sectionally. The EQ-5D-5L serves as a reasonable alternative or supplementary instrument to the FACT-B in assessing breast cancer patients' health outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 23054499     DOI: 10.1007/s11136-012-0291-7

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  18 in total

1.  Assessment of quality of life in palliative care--psychometric properties of a short questionnaire.

Authors:  B Axelsson; P O Sjödén
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

2.  Estimating an EQ-5D population value set: the case of Japan.

Authors:  Aki Tsuchiya; Shunya Ikeda; Naoki Ikegami; Shuzo Nishimura; Ikuro Sakai; Takashi Fukuda; Chisato Hamashima; Akinori Hisashige; Makoto Tamura
Journal:  Health Econ       Date:  2002-06       Impact factor: 3.046

Review 3.  A comparative review of four preference-weighted measures of health-related quality of life.

Authors:  Jacek A Kopec; Kevin D Willison
Journal:  J Clin Epidemiol       Date:  2003-04       Impact factor: 6.437

4.  The English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients.

Authors:  Chun Fan Lee; Raymond Ng; Nan Luo; Nan Soon Wong; Yoon Sim Yap; Soo Kien Lo; Whay Kuang Chia; Alethea Yee; Lalit Krishna; Celest Wong; Cynthia Goh; Yin Bun Cheung
Journal:  Support Care Cancer       Date:  2012-06-06       Impact factor: 3.603

5.  Preference-Based EQ-5D index scores for chronic conditions in the United States.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

6.  A Wilcoxon-type test for trend.

Authors:  J Cuzick
Journal:  Stat Med       Date:  1985 Jan-Mar       Impact factor: 2.373

7.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Authors:  M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 8.  Missing quality of life data in cancer clinical trials: serious problems and challenges.

Authors:  J Bernhard; D F Cella; A S Coates; L Fallowfield; P A Ganz; C M Moinpour; P Mosconi; D Osoba; J Simes; C Hürny
Journal:  Stat Med       Date:  1998 Mar 15-Apr 15       Impact factor: 2.373

9.  Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods.

Authors:  M F Janssen; E Birnie; G J Bonsel
Journal:  Qual Life Res       Date:  2008-03-05       Impact factor: 4.147

10.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

View more
  21 in total

Review 1.  Can The EQ-5D Detect Meaningful Change? A Systematic Review.

Authors:  Nalin Payakachat; Mir M Ali; J Mick Tilford
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

2.  Responsiveness of the EuroQoL 5-dimension (EQ-5D) in adolescent idiopathic scoliosis.

Authors:  Prudence Wing Hang Cheung; Carlos King Ho Wong; Sin Ting Lau; Jason Pui Yin Cheung
Journal:  Eur Spine J       Date:  2017-10-09       Impact factor: 3.134

3.  Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement.

Authors:  Barbara L Conner-Spady; Deborah A Marshall; Eric Bohm; Michael J Dunbar; Lynda Loucks; Ammar Al Khudairy; Tom W Noseworthy
Journal:  Qual Life Res       Date:  2015-01-03       Impact factor: 4.147

4.  Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness.

Authors:  Amaia Bilbao; Lidia García-Pérez; Juan Carlos Arenaza; Isidoro García; Gloria Ariza-Cardiel; Elisa Trujillo-Martín; Maria João Forjaz; Jesús Martín-Fernández
Journal:  Qual Life Res       Date:  2018-07-05       Impact factor: 4.147

5.  Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).

Authors:  Fan Yang; Titus Lau; Evan Lee; A Vathsala; Kee Seng Chia; Nan Luo
Journal:  Eur J Health Econ       Date:  2014-12-18

6.  Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.

Authors:  Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi
Journal:  Qual Life Res       Date:  2020-09-15       Impact factor: 4.147

7.  Health-related Quality of Life in Patients with Metastatic Spinal Cord Compression.

Authors:  Søren S Morgen; Svend A Engelholm; Claus F Larsen; Rikke Søgaard; Benny Dahl
Journal:  Orthop Surg       Date:  2016-08       Impact factor: 2.071

8.  Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites.

Authors:  M Moskovitz; K Jao; J Su; M C Brown; H Naik; L Eng; T Wang; J Kuo; Y Leung; W Xu; N Mittmann; L Moody; L Barbera; G Devins; M Li; D Howell; G Liu
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

9.  Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients.

Authors:  Dominik Golicki; Maciej Niewada; Anna Karlińska; Julia Buczek; Adam Kobayashi; M F Janssen; A Simon Pickard
Journal:  Qual Life Res       Date:  2014-11-26       Impact factor: 4.147

10.  Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?

Authors:  Nan Luo; Yin Bun Cheung; Raymond Ng; Chun Fan Lee
Journal:  Health Qual Life Outcomes       Date:  2015-10-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.